These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25981976)

  • 21. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia.
    Mikhailov D; Young HC; Linhardt RJ; Mayo KH
    J Biol Chem; 1999 Sep; 274(36):25317-29. PubMed ID: 10464257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of pH and ionic strength on the binding strength of anti-PF4/polyanion antibodies.
    Nguyen TH; Greinacher A
    Eur Biophys J; 2017 Dec; 46(8):795-801. PubMed ID: 28712066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit.
    Pierce W; Mazur J; Greenberg C; Mueller J; Foster J; Lazarchick J
    Ann Clin Lab Sci; 2013; 43(4):429-35. PubMed ID: 24247801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMR solution structure of the 32-kDa platelet factor 4 ELR-motif N-terminal chimera: a symmetric tetramer.
    Mayo KH; Roongta V; Ilyina E; Milius R; Barker S; Quinlan C; La Rosa G; Daly TJ
    Biochemistry; 1995 Sep; 34(36):11399-409. PubMed ID: 7547867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.
    Greinacher A; Pötzsch B; Amiral J; Dummel V; Eichner A; Mueller-Eckhardt C
    Thromb Haemost; 1994 Feb; 71(2):247-51. PubMed ID: 8191407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin-induced thrombocytopenia: frequency and pathogenesis.
    Greinacher A
    Pathophysiol Haemost Thromb; 2006; 35(1-2):37-45. PubMed ID: 16855345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prothrombotic potential of platelet factor 4.
    Thachil J
    Eur J Intern Med; 2010 Apr; 21(2):79-83. PubMed ID: 20206875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mode of interaction between platelet factor 4 and heparin.
    Maccarana M; Lindahl U
    Glycobiology; 1993 Jun; 3(3):271-7. PubMed ID: 8358152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.
    Prechel MM; Jeske WP; Walenga JM
    Thromb Res; 2010 Apr; 125(4):e143-8. PubMed ID: 19931120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molten globule monomer to condensed dimer: role of disulfide bonds in platelet factor-4 folding and subunit association.
    Mayo KH; Barker S; Kuranda MJ; Hunt AJ; Myers JA; Maione TE
    Biochemistry; 1992 Dec; 31(48):12255-65. PubMed ID: 1457422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights in heparin-induced thrombocytopenia by the use of fluid-phase assays to detect specifically platelet factor 4/heparin complex antibodies and antibody-secreting cells.
    Schulze A; Jensch I; Krauel K; Alahmad A; Müller HP; Greinacher A; Hundt M
    Thromb Res; 2014 Jul; 134(1):174-81. PubMed ID: 24816371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-transient "self-sustaining" heparin-induced thrombocytopenia: 4-year persistence of a platelet-activating PF4/heparin-antibody status without heparin exposure.
    Birschmann I; Gummert J; Schirmer U; Knabbe C; Sachs UJ; Koster A
    Platelets; 2014; 25(8):634-5. PubMed ID: 24246163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation.
    Rucinski B; Niewiarowski S; Strzyzewski M; Holt JC; Mayo KH
    Thromb Haemost; 1990 Jun; 63(3):493-8. PubMed ID: 2402751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet Factor 4 Interactions with Short Heparin Oligomers: Implications for Folding and Assembly.
    Niu C; Yang Y; Huynh A; Nazy I; Kaltashov IA
    Biophys J; 2020 Oct; 119(7):1371-1379. PubMed ID: 32348723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis.
    Carrier M; Knoll GA; Kovacs MJ; Moore JC; Fergusson D; Rodger MA
    Thromb Res; 2007; 120(2):215-20. PubMed ID: 17098277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-affinity platelet factor 4 1H NMR derived aggregate equilibria indicate a physiologic preference for monomers over dimers and tetramers.
    Mayo KH
    Biochemistry; 1991 Jan; 30(4):925-34. PubMed ID: 1989685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a heparin-binding protein on blood coagulation and platelet function.
    Kaiser P; Harenberg J; Walenga JM; Huhle G; Giese C; Prechel M; Hoppensteadt D; Fareed J
    Semin Thromb Hemost; 2001 Oct; 27(5):495-502. PubMed ID: 11668419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual effect of Platelet Factor 4 on the activities of Factor Xa.
    Fiore MM; Mackie IJ
    Biochem Biophys Res Commun; 2009 Feb; 379(4):1072-5. PubMed ID: 19150337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.